Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Homeostatic Imbalance01:10

Homeostatic Imbalance

31.7K
Homeostasis is the maintenance of a stable internal environment within the body, which is crucial for the proper functioning of cells, tissues, organs, and organ systems. The body has various control mechanisms that work together to regulate various physiological parameters such as temperature, blood pressure, pH balance, and fluid balance, to name a few. These control mechanisms are based on feedback loops that can be either positive or negative.
However, sometimes these feedback loops fail,...
31.7K
Hemoglobin01:24

Hemoglobin

7.1K
Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
7.1K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

3.8K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.8K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

3.0K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
3.0K
Hematopoiesis01:21

Hematopoiesis

8.3K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies.

British journal of haematology·2026
Same author

Structural variant discovery and diagnostic impact in rare diseases from short-read and long-read sequencing.

medRxiv : the preprint server for health sciences·2026
Same author

RAG-mediated structural variation and its impact on relapse risk in acute lymphoblastic leukemia.

medRxiv : the preprint server for health sciences·2026
Same author

Shifting IRES versus Cap-initiated translation during homeostatic stem cell differentiation and stress.

Science advances·2026
Same author

Genetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells.

Cell·2026
Same author

Epigenome editing of human hematopoietic stem cells enables sustained and reversible thrombosis prevention.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Dec 30, 2025

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.2K

Stabilizing HIF to Ameliorate Anemia.

Richard A Voit1, Vijay G Sankaran1

  • 1Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, USA.

Cell
|January 18, 2020
PubMed
Summary

Roxadustat inhibits HIF-prolyl hydroxylase (HIF-PHD), boosting erythropoietin (EPO) for anemia treatment. This improves iron absorption and anemia in chronic kidney disease patients.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Pharmacology

Background:

  • Kidney disease anemia is linked to impaired erythropoietin (EPO) production.
  • Hypoxia-inducible factor 1-alpha (HIF-1α) regulates EPO.
  • HIF-prolyl hydroxylase (HIF-PHD) degrades HIF-1α under normal oxygen levels.

Purpose of the Study:

  • To investigate roxadustat's effect on HIF-PHD.
  • To evaluate roxadustat's impact on EPO production and iron absorption.
  • To assess roxadustat's efficacy in treating anemia in chronic kidney disease (CKD).

Main Methods:

  • Inhibition of HIF-PHD enzyme activity.
  • Monitoring of erythropoietin (EPO) levels.
  • Assessment of iron absorption parameters.

More Related Videos

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K

Related Experiment Videos

Last Updated: Dec 30, 2025

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
05:35

Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management

Published on: January 19, 2024

1.2K
A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.9K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.2K
  • Clinical evaluation of anemia in CKD patients.

    • Main Results:

    • Roxadustat effectively inhibits HIF-PHD.
    • Inhibition leads to increased EPO production.
    • Improved iron absorption and anemia amelioration observed in CKD patients.

    Conclusions:

    • Roxadustat is a promising therapeutic agent for anemia in CKD.
    • HIF-PHD inhibition is a viable strategy for managing kidney disease anemia.
    • Roxadustat offers a novel approach to enhance erythropoiesis and iron homeostasis.